脂蛋白a在心血管疾病中的研究进展  

Research Progress of Lipoprotein a in Cardiovascular Diseases

作　　者：阿依谢姆·库尔班 刘志强[1] 

机构地区：[1]新疆医科大学第一附属医院,心脏中心,新疆 乌鲁木齐

出　　处：《临床医学进展》2023年第9期14796-14802,共7页Advances in Clinical Medicine

摘　　要：脂蛋白a [Lp(a)]是由含载脂蛋白APOB-100的低密度脂蛋白胆固醇样颗粒和载脂蛋白a组成的一种循环脂蛋白。Lp(a)通过促动脉粥样硬化、促炎症及促血栓形成等机制参与心血管疾病(CVD)发生、发展的病理生理过程,并独立于低密度脂蛋白胆固醇增加CVD风险,是CVD遗传、独立、因果因素。近年来,Lp(a)作为重要残余心血管风险备受关注,有望成为CVD降脂治疗新靶点。本文对Lp(a)概述、致病机制、Lp(a)与冠心病、钙化性主动脉瓣狭窄等疾病相关性及降脂治疗等方面的最新进展进行综述。Lipoprotein a [Lp(a)] is a circulating lipoprotein composed of low-density lipoprotein cholester-ol-like particles containing APO B-100 and APO a. Lp(a) is involved in the pathophysiological pro-cess of the occurrence and development of cardiovascular disease (CVD) through pro-atherosclerosis, pro-inflammation, pro-thrombosis and other mechanisms, and increases the risk of CVD independently of low-density lipoprotein cholesterol, which is a genetic, independent and causal factor of CVD. In recent years, Lp(a) has attracted much attention as an important resid-ual cardiovascular risk and is expected to become a new target for lipid-lowering therapy of CVD. In this paper, the overview of Lp(a), the pathogenesis, the correlation between Lp(a) and coronary heart disease, calcified aortic stenosis and other diseases, and the latest progress of lipid-lowering therapy were reviewed.

关 键 词：脂蛋白A 心血管疾病 进展 

分 类 号：R54[医药卫生—心血管疾病]